That may be a little difficult to come by for glax:
Canada’s Pest Management Regulatory Agency phased out of all agricultural uses of lindane between 2000 and 2005 due to concerns of chronic occupational exposure and risks to workers during seed treatment and planting. However, lindane medications remain available in Canada for public health purposes as non-prescription therapies. In 2002, the EPA concluded that lindane agricultural products were eligible for re-registration given industry compliance with certain data and labeling requirements to mitigate occupational risks to workers. However, in 2006, the Agency published an addendum to its initial decision and called for the voluntary cancellation of all agricultural uses by registered manufacturers (effective July 2007), citing a significant change in the costs and benefits of agricultural uses due to the recent introduction of seed-treatment alternatives to lindane. The EPA has approved the use of lindane stockpiles through 2009. Lindane medications remain available for public health purposes in the U.S. but, unlike Canada, are prescription-only therapies.
Lindane is banned in 52 countries, including some European and developing countries, and is under review for addition to the Stockholm Convention On Persistent Organic Pollutants. Mexico has committed to a structured, voluntary phase out of lindane through the North American Regional Action Plan (NARAP) but currently authorizes agricultural, veterinary and healthcare uses. California passed legislation banning pharmaceutical uses of lindane (effective 2002) and there is a bill in the New York State Assembly and Senate to ban its use in head lice products and limit its use on scabies, which had not passed as of September 2007. However, the FDA continues to support the use of lindane medications for the diseases they are indicated and approved.